Histologic Subtype of Metastatic Renal Cell Carcinoma Predicts Response to Combined Immunochemotherapy with Interleukin 2, Interferon α and 5-Fluorouracil
- 1 June 2007
- journal article
- Published by Elsevier in European Urology
- Vol. 51 (6) , 1625-1632
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- 2004 WHO Classification of the Renal Tumors of the AdultsEuropean Urology, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Histologic Predictors of Renal Cell Carcinoma Response to Interleukin-2-Based TherapyJournal of Immunotherapy, 2005
- Metastatic renal cell carcinomaCurrent Treatment Options in Oncology, 2003
- Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non–Clear-Cell HistologyJournal of Clinical Oncology, 2002
- Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell CancerNew England Journal of Medicine, 2001
- IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trialBritish Journal of Cancer, 2001
- Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialThe Lancet, 2001
- Rising Incidence of Renal Cell Cancer in the United StatesJAMA, 1999
- Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancerEuropean Journal of Cancer, 1993